7124 |
TUMOR NECROSIS FACTOR |
TNF |
DIF |
TNF-alpha |
TNFA |
TNFSF2 |
TNLG1F |
191160 |
11892 |
ENSG00000232810 |
OTTHUMG00000031194 |
P01375 |
TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 2 |
CACHECTIN |
TNF-A |
ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810 |
N-terminal fragment |
Tumor necrosis factor, soluble form |
C-domain 2 |
C-domain 1 |
Intracellular domain 2 |
Intracellular domain 1 |
Tumor necrosis factor, membrane form |
ICD2 |
ICD1 |
NTF |
PA435 |
TNFA_HUMAN |
T20178 |
Target Class | Miscellaneous |
Target Subclass | Ligand |
Target Subclass | Cytokine |
Target Class | Other |
Target Main Class | Other |
Transmembrane Helix Count | 1 |
Gene Biotype | PROTEIN_CODING |
CELL SURFACE |
EXTERNAL SIDE OF PLASMA MEMBRANE |
DRUGGABLE GENOME |
antibody (inhibitory) |
inhibitor (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
Mechanism of Interaction | TNF-alpha inhibitor |
inhibitor (inhibitory) |
Trial Name | ART621, PN0621 |
Novel drug target | Established target |
Mechanism of Interaction | TNF-alpha inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | TNF-alpha inhibitor |
Direct Interaction | yes |
Trial Name | ozoralizumab |
inhibitor (inhibitory) |
Mechanism of Interaction | TNF-alpha inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | TNF-alpha inhibitor |
inhibitor (inhibitory) |
Trial Name | infliximab ,Remicade |
Novel drug target | Established target |
Direct Interaction | yes |
antibody (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | TNF-alpha inhibitor |
Direct Interaction | yes |
Trial Name | Humira |
antibody (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | TNF-alpha inhibitor |
Trial Name | Enbrel |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | TNF-alpha inhibitor |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | TNF-alpha inhibitor |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | TNF-alpha inhibitor |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | TNF-alpha inhibitor |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | TNF-alpha inhibitor |
n/a |
Trial Name | PF-04236921 |
Novel drug target | Established target |
n/a |
Trial Name | dersalazine sodium |
Novel drug target | Established target |
inducer (activating) |
Notes |
n/a |
TNF | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
P01375 | Uniprot Accession |
ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810 | Ensembl Gene Id |
TNF | Gene Symbol |
Target Main Class | Other |
Target Subclass | Ligand |
Transmembrane Helix Count | 1 |
TNF | Gene Symbol |
Target Class | Miscellaneous |
Target Subclass | Ligand |
Target Subclass | Cytokine |
PA435 | PharmGKB ID |
TNF | TTD Gene Abbreviation |
T20178 | TTD Target ID |
ENSG00000232810 | Gene Symbol |
TNF | Ensembl Id |
DRUGGABLE GENOME |
TNF | Gene Symbol |
TNFSF2 | GENE_SYMBOL |
TNF | GENE_SYMBOL |
Tumor necrosis factor | UNIPROT |
TNFA | GO Gene Synonym |
TNFSF2 | GO Gene Synonym |
CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE |
TNF | Gene Symbol |
CLINICALLY ACTIONABLE |